The NeuroCytotron utilizes non-invasive, safe, tissue engineering technology that stimulates proteins which aid in the regeneration of brain cells
ROCKVILLE, Md., Jan. 30, 2023 /PRNewswire-PRWeb/ -- NeuroCytonix, Inc. (the "Company" or "NeuroCytonix") today announced that on January 19, 2023, its subsidiary NeuroCytonix Mexico has received a regulatory acknowledgment letter from the Mexican regulatory authority COFEPRIS – ref/memorandum number 223300ES450795/2023 – following the presentation of NeuroCytonix final report on its clinical trial on Cerebral Palsy NCX-CP-01.
The acknowledgment represents the legal and formal conclusion of the clinical trial, according to the methodology authorized by COFEPRIS. The resolution of the NCX-CP-01 clinical trial provides safety and efficacy data on investigational NeuroCytotron treatment of Cerebral Palsy. A manuscript detailing the results of this clinical trial is currently under preparation and will soon be submitted to several scientific journals.
The results of this clinical trial provide support for additional studies that will continue to evaluate the ongoing application of therapies with the NeuroCytotron in larger groups of patients, which will be supported by a Standard Operating Procedure where all cases will be recorded. This acknowledgment confirms that NeuroCytonix is a company that has formally concluded a clinical trial for its investigational NeuroCytotron treatment and is now registered in the National Registry of Research Companies in Mexico.
NeuroCytonix is an emerging biotechnology business founded in January 2017 to develop and exploit transformational medical technologies for the regeneration of the nervous system. The Company's technology and related protocols include Stroke, Autism, Cerebral Palsy and neurological consequences of Traumatic Brain Injury (TBI) and Covid19. The Company's core technology, the NEUROCYTOTRON, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins which aid in the regeneration of brain cells.
The NeuroCytonix technology is based on the work of its founder and CEO, Dr. J. Roberto Trujillo, an MD and PhD from Harvard University who has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. Dr. Trujillo has devoted his career to pioneering regenerative medicine technologies with the hope of transforming the status quo of healthcare for these previously believed incurable conditions.
NeuroCytonix has built a Research Center in Monterrey Mexico where it has trained and directed a clinical research team who has successfully implemented its first Cerebral Palsy clinical trial evaluating the safety and efficacy of the treatment.
Link to the full study on ClinticalTrials.gov.
Laurent Lavigne du Cadet
Chief Financial Officer
Laurent Lavigne du Cadet, NeuroCytonix, 1 2402436446, [email protected]